Solid Biosciences gene therapy trial put on hold for second time, shares slump

Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration had put on hold a trial testing its gene therapy for a muscle-wasting disorder, the second halt by the health regulator, sending its shares plunging 66%.